Genmab and Biontech expand their partnership

The Danish and German firms’ newest collaborative efforts target multiple cancer immunotherapy candidates.

Photo: Joost Melis / Genmab / PR

Genmab and partner Biontech are expanding their global strategic collaboration for new cancer immunotherapies, the firms announced in a joint press release on Friday.

The newer and bigger partnership seeks to develop and commercialize new monospecific antibody candidates for various cancer indications using Genmab’s proprietary Hexabody technology platform, the first of which, GEN1053/BNT313, will head to clinic at the end of 2022.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs